100s of titles, one news app for just $10 a month.
Latest Business news:
The Star executive chairman John O'Neill announces his resignation
The executive chairman of Star Entertainment Group, John O'Neill, has tendered his resignation and will step down from the board.
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
US Growth Seen Outpacing China’s for First Time Since 1976
China’s coronavirus lockdowns mean its economic growth may undershoot the US for the first time since 1976, in a role…
McDonald’s effort to ‘de-arch’ Russia is unlikely to prove easy
The brand is pulling out fully though its exit path looks trip-wired
Woolworths to buy MyDeal.com.au for $243m
Supermarket giant Woolworths is proposing to acquire MyDeal.com.au for $1.05 per share, a 63 per cent premium.
Economy changes despite political boasts
There has been a marked change in the Australian economy in a matter of weeks and largely out of the…
From analysis to good news, read the world’s best news in one place
How the major parties’ election tech promises stack up
Australians will head to the polls on Saturday following a long election campaign which was largely devoid of tech-focused policy…
ASX snaps four-week losing streak, Crown shareholders back $8.9b takeover
The Australian share market jumps in afternoon trade, despite another volatile day on Wall Street as investors weighed up the…

Analyst Ratings for Cytek Biosciences

By Benzinga Insights

Over the past 3 months, 4 analysts have published their opinion on Cytek Biosciences (NASDAQ:CTKB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 0 2 0 0
Last 30D 0 0 1 0 0
1M Ago 2 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 0 0 1 0 0

In the last 3 months, 4 analysts have offered 12-month price targets for Cytek Biosciences. The company has an average price target of $13.75 with a high of $18.00 and a low of $11.00.

Below is a summary of how these 4 analysts rated Cytek Biosciences over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average represents a 36.78% decrease from the previous average price target of $21.75.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.